C. Jeffrey Smith

Professor, Research Health Scientist
Radiopharmaceutical Sciences - School of Medicine
(573) 814-6000, Ext. 53683
smithcj@health.missouri.edu
http://medicine2.missouri.edu/rsi/jeff-smith.html
Term Ends: 2020

Dr. Smith is considered to be an expert in inorganic/organometallic/main group chemistry, with extensive training in the design and development of polydentate, water-soluble, complexing agents for various radiometals. He also has expertise in development of novel, theranostic (diagnosis and therapy), disease-seeking radiopharmaceuticals for animal and human use. This includes isotope processing and purification, tracer level metallation of small ligand frameworks and molecular cell-targeting agents, and in vitro and in vivo diagnostic/therapeutic probe development. Currently, his interest is in the design and development of monovalent and bivalent analogs and nanoparticles of gastrin releasing peptide (GRP), prostate specific membrane antigen (PSMA), and RGD (arginine-glycine-glutamic acid) radiolabeled with a host of radionuclides for diagnosis or therapy of human cancers.

Dr. Smith has been funded by the VA Merit Review Award mechanism and by the National Institutes of Health (National Cancer Institute and National Institute of Biomedical Imaging and Bioengineering). Dr. Smith currently serves as a consultant from the United States to the International Atomic Energy Agency (Vienna, Austria) on an important collaborative research project titled “Copper-64 Radiopharmaceuticals for Theranostic Applications”. He has an extensive publication record in numerous peer-reviewed journals including the Proceedings of the National Academy of Science, Cancer Research, Anticancer Research, Bioconjugate Chemistry, Nuclear Medicine and Biology, and the Journal of Nuclear Medicine. His total publication record includes 61 peer-reviewed journal articles, 9 book chapters, and 33 professional reports or proceedings from a meeting. The h-index, a numerical value assigned to describe the impact of his work, is currently 32.